Progressive Myoclonic Epilepsies

The progressive myoclonic epilepsies (PMEs) are a heterogeneous group of rare genetic disorders characterized by the triad of (1) action- and stimulus-sensitive myoclonus that worsens over time, (2) epileptic seizures (typically generalized tonic-clonic), and (3) progressive neurological deterioration, usually manifesting as cerebellar ataxia and cognitive decline. PMEs are distinct from the idiopathic generalized epilepsies (IGE) because of their progressive course, resistance to standard antiseizure medications, and ultimately devastating prognosis in many cases. The ILAE 2022 classification recognizes progressive myoclonic epilepsies as a group of syndromes with variable age of onset, associated with developmental and/or epileptic encephalopathy or progressive neurological deterioration. Early recognition of a PME syndrome and identification of the specific genetic etiology are essential because they inform prognosis, guide appropriate (and inappropriate) treatment choices, enable genetic counseling, and may open doors to disease-specific or experimental therapies.

Overview and Classification

Clinical Recognition

The PMEs share a core clinical phenotype that distinguishes them from other myoclonic epilepsies:

• Myoclonus: Begins as subtle, action-sensitive jerks that worsen over months to years; becomes increasingly disabling, interfering with walking, eating, writing, and self-care; stimulus-sensitive (provoked by light, sound, touch, or action)
• Seizures: Generalized tonic-clonic seizures are common; myoclonic seizures may be the predominant seizure type; atypical absences and other seizure types may develop
• Neurological decline: Cerebellar ataxia (progressive gait unsteadiness, dysmetria, dysarthria); cognitive decline (ranges from mild executive dysfunction to severe dementia depending on the etiology)
• EEG deterioration: Background slowing that progresses over time; generalized spike-wave or polyspike-wave; photoparoxysmal response; giant cortical potentials on back-averaging of myoclonus

Major PME Etiologies

Unverricht-Lundborg Disease (EPM1)

Clinical Features

Unverricht-Lundborg disease (ULD) is the most common PME worldwide and has the most favorable prognosis among the classic PME syndromes:

• Genetics: Autosomal recessive; caused by a homozygous dodecamer repeat expansion in the promoter region of the CSTB gene (chromosome 21q22.3), encoding cystatin B, a cysteine protease inhibitor; rare point mutations also reported
• Epidemiology: Endemic in Finland (Baltic myoclonus) and Mediterranean regions; incidence ~1 per 20,000 in Finland; found worldwide at lower frequencies
• Onset: Age 6–16 years (peak 10–12 years); myoclonus is usually the presenting symptom
• Myoclonus: Action-sensitive and stimulus-sensitive; initially intermittent, becoming increasingly severe and disabling over years; may cause falls and severe functional impairment; cortical origin (giant SEPs, positive cortical correlate on back-averaging)
• Seizures: Generalized tonic-clonic seizures, usually infrequent and often well controlled with ASMs
• Cognition: Relatively preserved for years to decades; mild cognitive decline may develop late in the disease course; dramatically better than Lafora disease
• Ataxia: Progressive cerebellar ataxia develops but is often mild compared with the myoclonus

Diagnosis and Treatment

• Diagnosis: Genetic testing for CSTB repeat expansion (standard PCR may miss expansion; Southern blot or repeat-primed PCR is needed); EEG shows generalized spike-wave with photosensitivity; giant SEPs
• Treatment: Valproate and clonazepam are the mainstay for myoclonus; levetiracetam is effective; perampanel has shown benefit in refractory cases; piracetam (high-dose, 8–24 g/day) has antimyoclonic properties; N-acetylcysteine has been explored as a disease-modifying agent (limited evidence)
• Prognosis: Patients survive for decades; the main source of disability is myoclonus rather than seizures or cognitive decline; some patients become wheelchair-bound due to myoclonus severity; life expectancy is reduced but patients may survive into their 60s or beyond

Lafora Disease (EPM2)

Clinical Features

Lafora disease is the most severe and rapidly progressive of the common PME syndromes, typically resulting in death within 10 years of onset:

• Genetics: Autosomal recessive; caused by pathogenic variants in EPM2A (encoding laforin, a dual-specificity phosphatase, ~50% of cases) or NHLRC1 (encoding malin, an E3 ubiquitin ligase, ~40% of cases); rare cases lack mutations in either gene
• Pathology: Lafora bodies — intracellular, PAS-positive, diastase-resistant polyglucosan inclusions found in neurons, myocytes, hepatocytes, and eccrine sweat gland duct cells; represent aberrantly branched, insoluble glycogen; result from dysregulated glycogen metabolism
• Onset: 10–19 years (peak 14–16 years); normal development prior to onset
• Clinical course:
  • Early phase (years 1–3): GTC seizures, myoclonus, visual hallucinations (occipital seizures), behavioral changes, academic decline
  • Middle phase (years 3–7): Rapidly progressive dementia, worsening ataxia, disabling myoclonus, increasing seizure frequency, loss of independence
  • Late phase (years 7–10+): Severe dementia, status epilepticus, bedridden state, death (often from aspiration pneumonia or status epilepticus)
• Occipital seizures: Visual hallucinations and transient cortical blindness are characteristic of Lafora disease and help distinguish it from other PMEs early in the course

Diagnosis

• Skin biopsy: Axillary skin biopsy demonstrating PAS-positive Lafora bodies in eccrine sweat gland duct cells; ~80% sensitivity; a positive biopsy is highly specific
• Genetic testing: Sequencing of EPM2A and NHLRC1; first-line diagnostic test in most settings; exome sequencing is appropriate
• EEG: Generalized spike-wave and polyspike-wave; progressive background slowing; photosensitivity; occipital discharges may be prominent; giant SEPs and VEPs
• MRI: Initially normal; progressive cerebral and cerebellar atrophy over time

Treatment and Emerging Therapies

• Symptomatic: Valproate, clonazepam, levetiracetam, and perampanel for seizures and myoclonus; zonisamide may have some benefit; aggressive management of status epilepticus
• Emerging therapies: Antisense oligonucleotides (ASOs) targeting glycogen synthase to prevent Lafora body formation; antibody-enzyme fusion proteins to degrade polyglucosan; metformin (reduces glycogen synthesis) under investigation; gene replacement therapy in preclinical development
• Prognosis: Uniformly poor; most patients die within 10 years of onset; NHLRC1 mutations may have slightly slower progression than EPM2A mutations in some series

Neuronal Ceroid Lipofuscinoses (NCL)

Overview

The neuronal ceroid lipofuscinoses (NCLs, also known as Batten disease) are a group of lysosomal storage disorders characterized by progressive accumulation of autofluorescent lipopigment (ceroid lipofuscin) in neurons and other tissues. They are the most common neurodegenerative disorders in children and represent an important cause of PME:

Diagnosis and Treatment

• Enzyme assays: PPT1 and TPP1 enzyme activity in leukocytes or dried blood spots (for CLN1 and CLN2, respectively); first-line screening tests
• Genetic testing: Targeted gene panels or exome sequencing; identifies the specific NCL type
• Electron microscopy: Skin or conjunctival biopsy showing characteristic storage material ultrastructure (GROD, curvilinear profiles, fingerprint profiles)
• Ophthalmology: Electroretinogram (ERG) shows progressive retinal degeneration; fundoscopy may show bull's-eye maculopathy, optic atrophy, or pigmentary retinopathy
• Treatment: Cerliponase alfa (recombinant TPP1) via intracerebroventricular infusion is FDA-approved for CLN2 disease; slows motor and language decline; gene therapy approaches under investigation for multiple NCL types; ASMs for seizure management (valproate, levetiracetam, clonazepam)

Sialidosis Type I

Clinical Features

Sialidosis type I (cherry-red spot myoclonus syndrome) is an autosomal recessive lysosomal storage disorder caused by deficiency of neuraminidase 1:

• Gene: NEU1 (neuraminidase 1; chromosome 6p21.3)
• Onset: Late childhood to young adulthood (8–25 years)
• Clinical features: Progressive action myoclonus (often severe); cherry-red spot on fundoscopic examination (bilateral, in ~95%); ataxia; GTC seizures; visual acuity usually preserved initially; NO hepatosplenomegaly or dysmorphic features (distinguishes type I from type II)
• Cognition: Generally preserved or only mildly affected (unlike most other PMEs)
• Diagnosis: Urine sialyloligosaccharides (elevated); neuraminidase enzyme activity in leukocytes or fibroblasts (deficient); NEU1 gene sequencing
• Treatment: Antimyoclonic ASMs (valproate, clonazepam, levetiracetam, perampanel); no disease-specific therapy available
• Prognosis: Slowly progressive; lifespan may approach normal; disability primarily from severe action myoclonus

Mitochondrial Causes: MERRF

Clinical Features

Myoclonic epilepsy with ragged-red fibers (MERRF) is a mitochondrial disorder that presents as a PME syndrome:

• Genetics: Mitochondrial DNA mutation; most commonly m.8344A>G in the MT-TK gene (tRNA^Lys); maternally inherited; heteroplasmy determines severity and age of onset
• Onset: Variable (childhood to adulthood); depends on heteroplasmy levels
• Core features: Myoclonus (action-sensitive, cortical); GTC seizures; ataxia; myopathy (proximal weakness, exercise intolerance)
• Associated features: Hearing loss (sensorineural); lipomas (multiple, symmetric, cervical); short stature; optic atrophy; cardiomyopathy; lactic acidosis (elevated serum lactate, particularly post-exercise)
• Muscle biopsy: Ragged-red fibers on modified Gomori trichrome stain; cytochrome c oxidase (COX)-negative fibers; subsarcolemmal mitochondrial accumulation

Diagnosis and Treatment

• Diagnosis: Mitochondrial DNA sequencing (blood or muscle tissue; muscle has higher sensitivity due to heteroplasmy); serum lactate and pyruvate; CK; muscle biopsy for histochemistry
• Treatment: Symptomatic ASMs (valproate is used with caution due to risk of hepatotoxicity in mitochondrial disorders — some experts avoid it entirely; levetiracetam, clonazepam, and perampanel are safer options); coenzyme Q10, L-carnitine, and B vitamins (limited evidence but widely used as mitochondrial supplements); exercise tolerance program; cardiac and endocrine screening
• AVOID: Valproate (risk of hepatic failure in mitochondrial disease, particularly POLG-related — less established for MT-TK but caution warranted); phenytoin; excessive fasting or metabolic stress

Diagnostic Approach to PME

Treatment Principles for PME

General Management

• Multidisciplinary care: Neurologist (seizure/myoclonus management), geneticist (diagnosis, counseling), psychiatrist (behavioral issues), physiotherapist (mobility), occupational therapist (adaptive devices), speech therapist (dysphagia), palliative care (when appropriate)
• Seizure management: Valproate (with caution in mitochondrial disease), levetiracetam, clonazepam, and perampanel are the most useful ASMs; brivaracetam may also be effective; piracetam (high dose) has antimyoclonic properties
• Avoid worsening agents: Phenytoin, carbamazepine, vigabatrin, gabapentin, pregabalin, and sometimes lamotrigine
• Myoclonus-specific management: Clonazepam is often the most effective single agent for action myoclonus; levetiracetam and perampanel are valuable add-ons; deep brain stimulation has been explored in severe refractory cortical myoclonus
• Supportive care: Wheelchair adaptation; feeding tube placement for severe dysphagia; seizure rescue plans; advance care planning

Disease-Specific Therapies

Rare and Emerging PME Etiologies

Beyond the classic PME syndromes, several rarer genetic etiologies have been identified through next-generation sequencing:

Palliative Care and Family Support

Given the progressive and often devastating nature of many PME syndromes, palliative care is an essential component of management:

• Advance care planning: Initiate early discussions about goals of care, particularly in rapidly progressive forms (Lafora disease, severe NCL); document preferences for aggressive seizure management, intubation, and resuscitation
• Symptom management: Aggressive treatment of myoclonus and seizures to maximize comfort and function; management of spasticity, pain, and secretions in advanced stages; attention to sleep quality and behavioral symptoms
• Nutritional support: Dysphagia is common in advanced PME; speech pathology assessment for swallowing safety; consideration of gastrostomy tube when oral feeding becomes unsafe
• Family and caregiver support: Genetic counseling for inheritance risk and reproductive options; psychological support for caregivers; connection to disease-specific support organizations (e.g., NCL Resource, Chelsea's Hope Lafora Research Fund)
• Clinical trial awareness: Encourage enrollment in natural history studies and therapeutic trials when available; registry participation (e.g., NCL Patient Database, DEM-CHILD registry) contributes to research progress
• Transition planning: As patients with childhood-onset PME survive into adulthood, coordinated transition from pediatric to adult neurology services is important; many adult neurologists have limited experience with PME

References

1. Riney K, Bogacz A, Somerville E, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset at a variable age. Epilepsia 2022;63(6):1443–1474.
2. Orsini A, Valetto A, Bertini V, et al. Progressive myoclonus epilepsy: a scoping review of diagnostic, phenotypic and therapeutic advances. Genes 2024;15(2):171.
3. Franceschetti S, Michelucci R, Canafoglia L, et al. Progressive myoclonic epilepsies: definitive and still undetermined causes. Neurology 2014;82(5):405–411.
4. Kalviainen R. Progressive myoclonus epilepsies. Semin Neurol 2015;35(3):293–299.
5. Krey I, Platzer K, Esterhuizen A, et al. Current practice in diagnostic genetic testing of the epilepsies. Epileptic Disord 2022;24(5):765–786.
6. Shahwan A, Farrell M, Delanty N. Progressive myoclonic epilepsies: a review of genetic and therapeutic aspects. Lancet Neurol 2005;4(4):239–248.
7. Minassian BA, Lee JR, Herbrick JA, et al. Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet 1998;20(2):171–174.
8. Joensuu T, Lehesjoki AE, Bhattacharjee A. Molecular background of EPM1-Unverricht-Lundborg disease. Epilepsia 2008;49(4):557–563.
9. Schulz A, Ajayi T, Specchio N, et al. Study of intraventricular cerliponase alfa for CLN2 disease. N Engl J Med 2018;378(20):1898–1907.
10. Sheidley BR, Malinowski J, Bergner AL, et al. Genetic testing for the epilepsies: a systematic review. Epilepsia 2022;63(2):375–387.
11. Berkovic SF, So NK, Andermann F. Progressive myoclonus epilepsies: clinical and neurophysiological diagnosis. J Clin Neurophysiol 1991;8(3):261–274.
12. Turnbull J, Tiberia E, Bhakta P, et al. Lafora disease. Epileptic Disord 2016;18(S2):38–62.